Advantage Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Advantage Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$14K	Buy	182 +11	+6%	+$914	0.01%	598
2019 Q2	$15K	Sell	171 -10	-6%	-$853	0.01%	598
2019 Q1	$16K	Sell	181 -304	-63%	-$25.9K	0.01%	575
2018 Q4	$35K	Buy	485 +139	+40%	+$11.2K	0.03%	406
2018 Q3	$33K	Buy	346 +62	+22%	+$6.01K	0.02%	480
2018 Q2	$27K	Hold	284	–	–	0.02%	486
2018 Q1	$25K	Hold	284	–	–	0.01%	516
2017 Q4	$24K	Buy	+284	New	+$23.8K	0.01%	541
2017 Q3	–	Sell	-100	Closed	-$8K	–	1123
2017 Q2	$8K	Hold	100	–	–	﹤0.01%	758
2017 Q1	$7K	Buy	+100	New	+$6.72K	﹤0.01%	762

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Advantage Investment Management's XBI Position: Q3 2019 in Review

Advantage Investment Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 6.4% in Q3 2019, buying an estimated $914 and bringing the position to 182 shares worth $14K. The position accounts for 0.01% of the portfolio, ranked #598.

Advantage Investment Management first reported a position in XBI in Q1 2017 and has held it in 10 quarters since. The position peaked at $35K in Q4 2018. 406 funds tracked by Wall St. Rank hold XBI as of Q3 2019.

Advantage Investment Management held 182 shares of State Street SPDR S&P Biotech ETF worth $14K as of Q3 2019.
Advantage Investment Management bought 11 State Street SPDR S&P Biotech ETF shares in Q3 2019, an estimated $914.
State Street SPDR S&P Biotech ETF made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #598 holding.
Advantage Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 10 quarters since.
Advantage Investment Management's State Street SPDR S&P Biotech ETF position peaked at $35K in Q4 2018.
406 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.